EXECUTIVE SUMMARY
The UK National Health Service (NHS) is developing rapidly. During this time of change there are many resource pressures on the overall healthcare system. There are also drivers being developed which aim to improve the consistency and quality of care for all patients. The British Thoracic Society (BTS) recognises these challenges and is an advocate for high quality standards in respiratory care. This statement has been developed from major evidence-based guidelines by an expert group with wider consultation including primary care colleagues in the General Practice Airways Group. It is aimed at those who commission and quality assure respiratory care as well as those involved in delivering this care.
The BTS recognises that, in many areas, development of integrated care pathways and initiatives to improve care with earlier discharge from hospital, prevention of admission strategies and fast track outpatient clinics are developing with a variety of experiences. These are intended to improve the patient's experience of care, the quality of care and the effectiveness of the care provided.
We hope that this statement will allow positive collaboration between primary and secondary care-and discussion between clinicians and commissioners. The areas covered pertain to the commonest causes of respiratory admission in the adult population, and are relevant no matter who refers and who manages the care of the patient. We recognise that, at times, individual uncertainties in clinical practice and balanced clinical judgement will result in practice outside the guidance. However, we hope these will be relatively few and for understandable reasons.
Some areas of the statement are aimed at common problems which result in high-cost hospital admission and high health care costs; others are aimed at rarer conditions. It should be remembered that some of the rarer conditions can be a large ''hidden'' cost to the NHS-all of these are very important to our patients.
We hope this statement will be used by: c service planners and developers c commissioners of respiratory services c providers of unscheduled care and emergency services c clinicians in primary care (medical, nursing and others)
c clinicians in medical assessment units. It is not aimed specifically at the following groups, but they will find it useful to read as an adjunct to the current BTS guidelines: c clinicians in secondary care (medical, nursing and others)
c patient user groups c audit and quality assurance departments.
The statement provides guidance on the following clinical disease areas: c asthma c chronic obstructive pulmonary disease (COPD) c lung cancer and mesothelioma c pneumonia c pulmonary embolism c obstructive sleep apnoea c other rarer conditions including bronchiectasis, lung fibrosis, sarcoidosis and tuberculosis. The guidance suggests the acceptable indications for:
INTRODUCTION Background
The need for this document has arisen with the changing emphasis of care in the UK NHS from hospital to community-based care. This has resulted in a drive for Primary Care Trusts (PCTs) to strengthen community care.
In the UK, Western Europe and the USA there has been emphasis on changing the way both acute and chronic diseases are managed. The degree of change differs between countries and areas within each country, but has generally shared the following aims: c reduction in the rate of hospital attendancesalso intended that this guidance statement might form the basis for the creation of pathways for the management of respiratory conditions in the future.
The proposed shift of care to the community where specialist knowledge and sophisticated investigations are not routinely available has created a justifiable anxiety on the safety of patient management. Mindful of the rapid changes in healthcare provision, the BTS Standards of Care Committee has taken the view that a statement highlighting criteria for specialist outpatient referral, hospitalisation, discharge and follow-up would help the wide range of professionals involved in respiratory care to streamline the management of patients while maintaining a good and safe standard of care.
The facts in these documents are rooted in many documents established by the BTS, European Respiratory Society (ERS) and the American Thoracic Society (ATS). It is recognised that this is a rapidly developing area of care and that this guidance will need to be updated on a regular basis.
Primary-secondary interface
The NHS plan encourages the development of integrated care. The principles to allow implementation of integrated care can be summarised as follows: c Social change and health promotion is developed to give a healthy lifestyle for the many, not the few.
c Patients (advised by the professionals) are the primary decision makers about their own health.
c Care should be given as near to the patient's home as is practical. Care needs to be rooted in primary care settings and underpinned by vastly improved communication and new partnerships across the whole health and social care spectrum.
c Care should be provided by professionals who know the patient and can form a supportive relationship. In patients with long-term conditions, this is paramount.
c Only when care cannot be provided to the appropriate clinical standards in the community should the patient be admitted to the acute hospital.
c The key to all care is the patient and professional encounter. The full health and social record must be available at this encounter for it to be effective. This will lead to a more dispersed service. Many patients suffer from the common respiratory long-term conditions chronic obstructive pulmonary disease (COPD) and asthma. These form a large component of those patients requiring chronic care programmes. 1 The evidence that chronic care works has been reviewed. 2 There is only evidence for positive outcomes in well-defined areas but overall conclusive grade 1 evidence is lacking. For example, robust studies showing that chronic management in COPD reduces the frequency of hospital admissions or unscheduled visits to the accident and emergency department need to be undertaken. 3 However, pilot schemes in practices (Castlefields) or PCTs (East Lincolnshire) have given encouraging results. In East Lincolnshire the model adopted included: c development of lead clinicians for COPD in the participating practice c provision of a template for systematic care of patients with COPD c adaptable education programme for participating clinicians c regular monitoring and support practice visits by a team of primary and secondary care specialists c establishment of COPD clinical forums for participating clinicians c provision of equipment to participating practice (spirometer and pulse oximeter funding for specific COPD clinics in general practice). This primary care initiative showed a 22.4% reduction (crude rate per 1000 population) for emergency COPD admissions following implementation of phases 1 and 2 (1999-2003) .
Figures from core practices show this to be sustained. One neighbouring PCT showed no reduction in emergency admissions and another PCT had a fall of 7.5%.
In 2003 a Cochrane systematic review 3 concluded that Hospital-at-Home was a safe and effective approach for selected patients with exacerbations of COPD and suggested that one in four patients presenting to hospital as an emergency would be suitable for home treatment with nursing support.
The keys to success
For this reorganisation of care to be implemented, it is vital that respiratory care is planned across a health economy, breaking down barriers between primary and secondary care. The components for success include the following.
Vision
All organisations should plan services against the principles of integrated care. Each must look at the whole health and social care economy in its entirety and what this means for the individuals in their care.
Clinically-led involvement
Patients are involved in their own care and patients and professionals set the standards for care.
Care pathways, documentation and communications
For a dispersed but integrated system of care to work, information and communication must be slick. It must cross all organisational interfaces. Indeed, for the patient the interface should be invisible-health and social care should be unified. Respiratory specialists must be involved in this work, using their expertise to aim for implementation of high standards of care across their district.
METHODOLOGY
A working party was established by the BTS Standards of Care Committee in January 2006. The steps towards formulating this document were as follows: c Disease specific statements were produced by lead authors. c A subcommittee of the Standards of Care Committee reviewed the initial statements.
c The final copy incorporated the comments of the BTS Standards of Care Committee/Council members and IMPRESS. Whenever possible the document follows the following template. However, because some diseases are by their nature either acute or chronic, the structure of that section will reflect only the appropriate section of the template. c The burden of disease c ICD10 codes c Ambulatory care -Criteria for referral to respiratory specialists -Criteria for follow-up in a respiratory specialist clinic -Criteria for discharge from a respiratory specialist clinic -Frequency of follow-up c Acute phase of disease -Assessment -Hospital-at-Home -Criteria for hospital admission -Criteria for hospital discharge -Criteria for follow-up in specialist care -Criteria for discharge from follow-up in a specialist clinic ASTHMA Burden of disease 4 5 The prevalence of asthma in the UK is one of the highest in Europe. Over 14% of children have asthma. Asthma poses a major problem to the patients and to the health care community.
In the UK in 2000 almost 3.9 million GP consultations for asthma took place. In 1999 there were just fewer than 74 000 hospital admissions for asthma symptoms. The cost of asthma care in the UK is in the region of £1.2 billion, £850 million of which is borne by the NHS and the rest represents loss of productivity as a result of asthma.
ICD10 codes
Asthma: J45; status asthmaticus: J46.
Ambulatory care
Regular review of patients with asthma by primary care nurses, primary care physicians or secondary care physicians is associated with favourable clinical outcome including reduced school and work absence, a reduced exacerbation rate and improved symptom control. [6] [7] [8] Most patients can control their asthma with regular support from primary care. All patients should be encouraged to keep a symptom and a peak flow diary.
Criteria for referral to a respiratory specialist outpatient clinic for patients with newly diagnosed asthma or pre-existing asthma 4 Refer if any of the following are present: c doubt about the diagnosis of asthma c uncontrolled asthma symptoms despite optimal management c suspected co-morbidity such as a component of heart failure, suspected malignancy, co-existing COPD c difficult asthma with persistent symptoms despite the use of optimal therapy advocated at step 4 on the BTS algorithm 4 Discharge from ambulatory care 4 The routine clinical review of patients with asthma is associated with improved clinical outcome including reduction in the rate of asthma exacerbations. The outcome of care does not differ whether this is done by doctors, nurses or pharmacists.
It is recommended that general practitioners (GPs) and primary care nurses keep a list of patients with asthma and their medications, and that a structured clinical review takes place at least annually.
Acute phase of disease
Several confidential inquiries [9] [10] [11] [12] into deaths from asthma attacks have shown that most deaths occurred outside hospital. Most deaths were in patients with chronic asthma. Inadequate treatment and underprovision of written management plans were observed in some deaths. Lack of prompt administration of oral or inhaled corticosteroids was a major factor.
Most asthma exacerbations can be treated in the community with regular review to alert for criteria to refer to hospital.
Criteria for referral to hospital during an acute exacerbation c Lack of response to treatment, including lack of improvement of peak expiratory flow (PEF) to .50% of best or predicted despite treatment for 24 h.
c Severe symptoms including inability to complete sentences, impairment of consciousness or impairment of haemodynamics.
c Silent chest during auscultation raising the possibility of severe asthma or pneumothorax.
c Patients with a history of severe uncontrolled asthma who live alone or where home circumstances do not allow adequate supervision.
c Patients with an unclear diagnosis and who are acutely unwell.
Life-threatening asthma: risk factors
Patients with high-risk factors should be kept on a register known to the asthma specialist service. Discharge from hospital: timing and criteria 4 c stability of symptoms on discharge medications for 24 h c PEF .75% of recent best or predicted and diurnal variation of ,25% unless discharge has been agreed with a respiratory physician c patient demonstrating an understanding of their symptoms and knowing when and whom to ask for help c patients demonstrating understanding of the purpose of their medications and competence in using inhaled medications appropriately c patients with home circumstances that the multidisciplinary team deems to be safe and adequate to seek help upon further attacks c appointment with GP or practice nurse within 2 weeks and/ or with a specialist respiratory physician or specialist asthma nurse within 4 weeks.
Follow-up after hospital discharge 4
Routine follow-up improves outcome for patients with asthma: c all patients must be followed up by a practice nurse or a GP c patients' symptoms and peak flow should be assessed c cigarette smoking status and smoking cessation counselling according to BTS guidelines for all smokers c frequency of follow-up should be decided by the GP c patients who needed specialist referral for uncontrolled asthma attacks should be reviewed at least once every 6 months c all patients with asthma should be listed as high risk in each general practice.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Burden of disease 13 14 The prevalence of COPD in the UK is around 1.5%. Approximately 900 000 people have symptoms and signs of COPD; 7% of men over 75 years of age suffer from COPD. The Lung Report III 14 by the British Lung Foundation indicated that only one in four patients with COPD is diagnosed.
The cost of COPD is considerable. In a district serving a population of 250 000 there are over 14 000 consultations for COPD annually. The cost of hospitalisation for COPD in 2001-2 amounted to £587 million in the UK. In addition, COPD costs 20.4 million lost working days among men in the UK.
Early diagnosis, prevention and management of stable COPD should occur within primary care by trained clinicians. They should be categorised on spirometry into mild (forced expiratory volume in 1 s (FEV 1 ) .80% predicted), moderate (60%.FEV 1 .30%) and severe (FEV 1 (30%).
ICD10 codes
COPD; J44; emphysema: J43.
Ambulatory care 13 15 Patients should be reviewed at least annually in primary care. The frequency and assessments needed during follow-up are shown in table 1.
Patients may have depression needing assessment and treatment. They should have access to self-help groups such as the Expert patient programme and Local Breathe Easy Club.
Criteria for referral to a specialist respiratory outpatient clinic 13 Referral for specialist advice may occur at any stage of the disease. The criteria for referral to a specialist respiratory outpatient clinic are shown in table 2.
Assessment of patients by a respiratory specialist 13 Respiratory specialists aim to manage COPD and its complications using appropriate steps tailored to the patient's history and evolving investigations including: c clinical history and physical examination c chest radiograph c detailed lung function tests including assessment of thoracic volume and gas transfer Discharge from respiratory specialist clinics to primary care 13 This includes: c patients with stable symptoms in a patient in whom the diagnosis of COPD is firmly established c patients who express a wish to be followed up in primary care after advice from the GP and specialist.
Follow-up by a respiratory specialist clinic 13 Most patients with COPD can be satisfactorily managed in primary care. Specialist follow-up should be considered for the following: c those with frequent exacerbations c patients on long-term oxygen therapy or nebulised bronchodilators c patients awaiting confirmation of diagnoses other than COPD c patients referred for lung transplantation or lung volume reduction surgery c patients who express a wish to be followed up by respiratory specialists after advice from the GP and specialist c patients with chronic hypoxia who are not yet on long-term oxygen therapy. The frequency of follow-up depends on the severity and stability of symptoms. Consider discharge as soon as the patient is stable.
Criteria for discharge from all ambulatory care 13 Non-smoking patients with very mild COPD with little or no exercise limitation can be discharged from follow-up but should be advised to be seen by their primary care team if the severity of their symptoms increases.
Acute phase of disease 13 An exacerbation of COPD is defined as follows: ''A sustained worsening of symptoms, beyond the day-to-day variation, that is acute in onset. Commonly reported symptoms are worsening of breathlessness, cough, and increased sputum production and change in sputum colour. The changes often require change in pharmacological management.'' COPD exacerbations are common. They are correlated with impaired quality of life, accelerated decline in lung function and increased healthcare costs. Most deaths from COPD are attributed to COPD exacerbations.
Some COPD exacerbations can be managed at home after assessment by specialist teams, but some need additional treatment that requires hospital referral. These criteria are not absolute. Ultimately it is a matter of clinical judgement whether or not a patient should be referred to the hospital.
Criteria for referral to hospital during acute exacerbations 13 c Signs of severe exacerbations: marked dyspnoea, tachypnoea, acute confusion, new onset of cyanosis, new signs of cor pulmonale The Hospital-at-Home arrangement is now well established practice in the UK, Western Europe, Australia and the USA. Selected patients are discharged early from hospital and are supervised by a team comprising specialist nurses and/or physiotherapists led by a respiratory specialist until they are discharged from the scheme to the care of a community matron, community COPD/respiratory team or their general practices.
Early discharge for patients with COPD is both cost-effective and favoured by patients. There is no evidence that it is associated with a poorer outcome than hospital management whether this is measured by change in FEV 1 , mortality or health-related quality of life.
Full BTS guidelines on intermediate care Hospital-at-Home in COPD 3 are available. These guidelines outline suitable criteria for Hospital-at-Home care for patients with COPD as well as level of staffing, minimal competency needed for staff caring for patients at home and basic investigations required to assess patients in their home environment.
Intermediate care Hospital-at-Home during an acute exacerbation should not be offered to patients who meet the accepted criteria for hospitalisation previously listed. Patients who can be treated at home and those who should be removed from the scheme during exacerbations and referred to hospital are shown in table 3.
Assessment of recovery from exacerbations for hospitalised patients 13 Recovery from COPD exacerbations is assessed by clinical improvement combined with improvement of basic signs including respiratory rate, pulse and oxygen saturation. Arterial blood gases need to be monitored in patients admitted with exacerbations who have had hypoxia with or without hypercapnic acidosis.
Spirometry or peak flow measurement should not be relied upon as the degree of recovery is small and can lag behind clinical improvement.
Recommendations at discharge 13 c Patients should be established on discharge medications which may include short-term nebuliser therapy for at least 24 h.
c Patients who were admitted with respiratory failure should have satisfactory oximetry or arterialised blood gases measured prior to discharge.
c All aspects of routine care need to be assessed prior to discharge.
c Patients or home carers should be given adequate information to help patients use their medications (including oxygen therapy).
c Arrangement for follow-up should be made for all patients admitted before discharge (see section on Ambulatory care).
c Before discharge the patient, physicians and allied health professionals should be confident that patients are able to cope in their home environment otherwise extra assistance should be put in place.
c Repeat of the chest radiograph is mandatory in patients with a new chest radiographic abnormality or those who were admitted with haemoptysis to exclude thoracic malignancy.
BRONCHIECTASIS (NOT DUE TO CYSTIC FIBROSIS)
BTS guidelines on bronchiectasis are due to be published in 2008.
Burden of disease
Bronchiectasis is defined as a dilatation and thickening of the airways manifested by cough, sputum production and frequent lower respiratory tract infection. The incidence is not known, but it has been estimated to be 1.06-1.3 per 100 000 population in the UK. It is a chronic condition so prevalence is much higher. In children, non-cystic fibrosis bronchiectasis was identified in 1% of all secondary care referrals in a UK population. The burden of bronchiectasis has not been investigated, but general practitioners, respiratory physiotherapists and respiratory physicians recognise that patients have frequent consultations and hospitalisation during infective exacerbations, disease complications and their care at the advanced disease status.
ICD10 codes
Bronchiectasis: J47.
Ambulatory care
As in COPD, follow-up of patients with mild to moderate disease will usually take place in primary care. For patients with severe disease, local arrangements between primary and specialist care should be made.
Management to reduce infections is recommended for followup of all grades of bronchiectasis, possibly written down in an action plan: c regular microscopy, culture and sensitivity of sputum at least yearly to inform choice of antibiotic when exacerbation occurs c vaccinations against influenza yearly and pneumococcus 10-yearly c arrangements for appropriate antibiotics to be given early if exacerbation threatens, self-administered by the patient if necessary c training in appropriate physiotherapy.
Criteria for referral to a respiratory specialist outpatient clinic 
Follow-up by a respiratory specialist clinic
The following should be followed up at a respiratory specialist clinic: c patients with chronic P aeruginosa colonisation c patients receiving prophylactic antibiotic therapy (oral or nebulised)
c patients with bronchiectasis and associated rheumatoid arthritis c patients with complex deteriorating bronchiectasis with declining lung function and recurrent exacerbations c patients on long-term oxygen therapy, nebulised bronchodilators or antibiotics c patients referred for lung transplantation c patients who express a strong wish to be followed up by a respiratory specialist.
Assessment of patients by a respiratory specialist
The following steps of assessment are emphasised: c CT scan of the thorax Discharge from respiratory specialist clinics to primary care
The following groups of patients can be discharged from the respiratory specialist clinic to primary care: c patients with stable mild symptoms in whom diagnosis of bronchiectasis is established c patients who express a wish to be followed up in the community.
Criteria for discharge from ambulatory care
Patients with very mild bronchiectasis with little or no exercise limitation or few infective exacerbations can be discharged from follow-up but should be advised to be seen by their primary care team if the severity of their symptoms increases.
Acute phase of disease Criteria for referral to hospital during acute exacerbations
An acute exacerbation of bronchiectasis is an acute and sustained increase in symptoms that requires treatment with oral or intravenous antibiotics. Many patients with exacerbations of bronchiectasis can be managed at home, but some need additional treatment that requires hospital referral. The criteria for hospitalisation for patients with bronchiectasis are similar to those with COPD. These include: c signs of severe exacerbations (marked dyspnoea, tachypnoea, acute confusion, new onset of cyanosis, new signs of cor pulmonale) c significant haemoptysis c the need for intravenous antibiotics at a level which might require monitoring with blood tests c inability to eat or sleep due to symptoms c rapid rate of onset of exacerbation c patients already on long-term oxygen therapy c the need for treatment not available at home such as oxygen therapy and nebulised agents c inadequate home support or living alone c impaired physical functions or inability of patients to cope at home c acute or chronic impairment of cognition.
Management of infective exacerbations at home (Hospital-at-Home arrangement)
Hospital-at-Home for bronchiectasis has not been evaluated to the same extent as for COPD. However, some centres offer this under the same criteria as COPD. The BTS guidelines do not recommend Hospital-at-Home for bronchiectasis.
Assessment of recovery from exacerbations for hospitalised patients
Recovery from bronchiectasis exacerbations is assessed identically to COPD. In addition, clearance of infection from the sputum is monitored by lightening of colour, decreased viscosity and amount.
Recommendations at discharge c Patients should be established on discharge medications for at least 24 h.
c All aspects of routine care need to be assessed prior to discharge. This should include an action plan of how to act in an exacerbation.
c Before discharge the patient, physicians and allied health professionals should be confident that patients are able to cope in their home environment, otherwise extra assistance should be put in place.
c A repeat chest radiograph is mandatory in patients with a new chest radiographic abnormality or those who were admitted with new unexplained haemoptysis to exclude thoracic malignancy.
CYSTIC FIBROSIS
Cystic fibrosis (CF) is recognised to be a specialist area. All patients should be managed by recognised secondary care Cystic Fibrosis Centres. Studies have found that there is a benefit in the outcome of care in favour of patients cared for by such specialist centres compared with those managed by nonspecialist units.
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ICD10 code
Cystic fibrosis: E84.
COMMUNITY-ACQUIRED PNEUMONIA Burden of disease 17 18 Pneumonia is inflammation of lung tissue which is due usually to infection with bacteria, viruses or fungi. It presents as an acute illness ranging in severity from mild to fatal. Over 66 000 people died from pneumonia in the UK in 1999. In the adult population it has an annual incidence of 5-11 per 1000 population and 22-42% of these are admitted to hospital; 5-10% of adults admitted to hospital with pneumonia require ICU management.
A prevalence-based burden of illness study estimated that pneumonia incurred a direct health care cost of £441 million annually at 1992-3 prices in the UK, and that hospital costs accounted for 87% of the total.
ICD10 codes
Influenza and pneumonia: J09-J18.
Acute phase
Decide early whether the patient can be managed at home or in hospital. For all patients, the decision to treat at home or refer to hospital is a matter of clinical judgement.
Assessment for hospital admission [19] [20] [21] Referral to hospital is primarily based on clinical judgement with an assessment of severity. An aid to clinical judgement is given in box 1. The core clinical features of Confusion, Respiratory rate, Blood pressure and age are known as CRB-65. c Patients who have a CRB-65 score of 0 are at low risk of death and do not normally require hospitalisation for clinical reasons.
c Patients who have a CRB-65 score of 1 or 2 are at increased risk of death and hospital referral and assessment should be considered, particularly with score 2.
c Patients who have a CRB-65 score of 3 or more are at high risk of death and require urgent hospital admission. In addition to disease severity, the three main factors influencing the decision to refer to hospital are (1) stability of pre-existing illnesses, (2) the patient's social circumstances and (3) the patient's wishes. These factors must be taken into account in all instances (box 2).
Pneumonia treated in the community [19] [20] [21] Individuals with pneumonia can often be managed at home. c Those managed at home need a review to assess disease severity (initially within 48 h of the primary consultation or sooner if clinically indicated) and its complications.
c Patients may require hospital admission if there is a failure to improve or they develop complications such as confusion, raised respiratory rate, hypotension, hypoxaemia or signs of complications such as septicaemia, pleural effusion/ empyema, dehydration, renal failure or lung abscess.
c In individuals whose pneumonia is treated successfully at home, specialist referral is indicated in those in whom an underlying lung disease is suspected such as chronic lung disease or lung cancer and failure of resolution of symptoms.
Criteria for discharge from hospital [19] [20] [21] Those suitable for discharge should demonstrate clinical stability and usually not have more than one of the following: c temperature .37.8uC c heart rate .100 beats/min c respiratory rate .24 breaths/min c systolic blood pressure ,90 mm Hg c oxygen saturation ,90% c inability to maintain oral intake c altered mental status.
In reality, particularly in the elderly, many factors such as the presence of co-morbidities and social support will affect the timing of discharge from hospital. It is essential that individuals are discharged to an appropriate environment.
Criteria for follow-up after hospital admission [19] [20] [21] Review is recommended around 6 weeks after hospital admission. This can be with the GP or in a specialist clinic. The hospital team must communicate with the GP regarding followup arrangements. Follow-up in a specialist clinic is usually indicated in those who have: c persistent abnormal symptoms and physical signs c complications of pneumonia c high risk of malignancy (smokers) c known or suspected underlying lung disease.
These individuals will require careful clinical and radiological assessment at follow-up. Further investigations such as bronchoscopy are recommended in this group.
Discharge from follow-up [19] [20] [21] Patients can be discharged from follow-up when: c there has been clinical and radiological resolution of the pneumonia c resolution or treatment of complications.
PNEUMOTHORAX
This document concerns primary (spontaneous) pneumothorax (PSP) in patients with no underlying lung disease and secondary pneumothorax (SP, spontaneous pneumothorax in patients with underlying lung disease) but not pneumothorax secondary to trauma.
Burden of disease 22
An average health district of 300 000 can expect approximately 70 hospital admissions each year for PSP and SP combined. This is an acute condition that needs rapid assessment by the specialist respiratory team for both immediate management and also long-term advice concerning recurrence prevention. 
ICD10 codes
Pneumothorax: J93.
Acute phase of disease 22 
Assessment
A senior member of the respiratory team (specialist registrar or consultant) should assess all cases of pneumothorax as soon as possible. This could be in a respiratory clinic, an emergency ''hot'' clinic, on the medical admissions unit or in the A&E department (this is the least preferable choice as it is associated with fewer adherences to national guidelines). The assessment should consist of: c pulse, blood pressure and oxygen saturation measurements and chest radiography (standard posterior-anterior (PA) view is sufficient) in all patients c arterial blood gas measurements in patients with SP c treatment with simple aspiration or intercostal chest drain as advised by the BTS guidelines. Patients with PSP whose symptoms resolve with simple aspiration of air from the pleural cavity may be discharged home after initial treatment with written advice to return immediately if the condition deteriorates.
Criteria for hospital admission
c All patients with a tension pneumothorax. c Patients with PSP who fail the criteria for conservative management and/or have failed an aspiration attempt and therefore need treatment with an intercostal drain.
c All patients with SP should be admitted and observed for a minimum 24-hour period, which also allows for evaluation and treatment of the underlying lung condition.
c Wider use of thoracic vents or flutter valves may allow early discharge of patients with PSP who fulfil the criteria for hospital admission.
Criteria for discharge from hospital c Those who have had a successful treatment with simple aspiration or intercostal drain with underwater seal (ie, resolution of symptoms and/or a rim of air ,2 cm).
c For SP, the underlying condition should also have returned to a stable state (see criteria for asthma and COPD).
c All patients should be reviewed by the respiratory team, even if this is in the clinic.
Criteria for surgery
c Second or subsequent pneumothorax. c Pneumothorax fails to resolve after 5 days in PSP or 3 days in SP, the specialist respiratory team should assess for surgery.
Criteria for follow-up
All cases should have a repeat chest radiograph and assessment in 1 month. c This could be undertaken in primary care for PSP cases unless definitive surgery is contemplated.
c For SP, a 1-month review should be undertaken in a specialist unit to assess stability of the underlying lung disease and to discuss imaging by CT scanning with a view to thoracic surgical intervention. This will depend on the severity of the effects of the pneumothorax on the patient when admitted and their underlying conditions. LUNG CANCER AND MESOTHELIOMA Burden of disease 23 24 During 2001-2003 there was an average of 33 346 deaths per annum from lung cancer in the UK and the annual incidence was 37 514. 23 Lung cancer is the most common fatal cancer, killing 30% more patients than breast and colorectal cancer combined. The 5-year survival is 6% for men and 7% for women. In the same period there was an average of 1720 deaths per annum from mesothelioma (more than those from cervical cancer, malignant melanoma or endometrial cancer). The incidence of mesothelioma is still rising and is expected to peak between 2010 and 2015. Between 2006 and 2020 up to 30 000 people will die of the disease in the UK.
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ICD10 codes
Trachea, bronchus and lung cancer: C33-34; mesothelioma: C45.
Ambulatory care 25 26 A patient who presents with symptoms, signs or investigations suggestive of lung cancer or mesothelioma should be urgently referred to a team specialising in the management of lung cancer and mesothelioma.
Investigations prior to referral to specialist team
Refer urgently for a chest radiograph a patient who presents with: c haemoptysis c any unexplained persistent (lasting .3 weeks) symptoms and signs shown in table 4 c unexplained changes in existing symptoms in patients with underlying chronic respiratory problems c features suggestive of metastasis from a lung cancer (eg, in brain, bone, liver or skin)
c individuals with a history of asbestos exposure and recent onset of chest pain, shortness of breath or unexplained systemic symptoms. The chest radiography report should be returned to the referring primary healthcare professional within 5 days of referral. 
Best supportive care
Offer a specialist review clinic or ward consultation by a team specialising in lung cancer and mesothelioma which may be led by a specialist nurse. Depending on the wishes of the patient, subsequent care could be follow-up in specialist care, in the community or both. There must be a clear route back into specialist care.
Active palliative treatment
Specialist follow-up is required with appropriate specialists depending on the treatment received and the patient's needs. There should be the option of nurse-led ''stock-take'' clinics during this period, with the support and supervision of the MDT. Extended follow-up may be with the specialist or protocol driven nurse-led follow-up. Upon relapse or development of recurrent symptoms, the patient must be referred back to the specialist or to the lung cancer/mesothelioma MDT.
Treatment with curative intent
Specialist follow-up is required to detect complications of treatment. The duration of this will depend on the individual patient. There should be the option of nurse-led ''stock-take'' clinics during this period. Extended follow-up may be a combination of protocol driven nurse-led clinics, specialist follow-up and rapid assessment of new symptoms.
Criteria for discharge from specialist follow-up
Discharge should be considered in: c Asymptomatic patients on best supportive care or completed active palliative treatment.
c Patients who have survived 5 years following curative treatment and have no symptoms or signs that suggest recurrence. Some specialists may wish to lengthen or shorten this period.
c Patients during the terminal phase of their disease who are too ill or who do not wish to attend specialist care. Although patients with lung cancer and mesothelioma may be discharged from follow-up by the specialist team, there must be a mechanism for rapid resumption of follow-up, either by direct admission or outpatient attendance.
Acute phase of disease Criteria for hospital admission
Patients should be admitted directly under the care of the team specialising in lung cancer and mesothelioma.
Planned admission
Patients with lung cancer and mesothelioma may require planned admission to hospital for diagnostic test(s) or treatment.
Urgent review or admission
Arrange review which may lead to admission with the specialist team at any stage in the care pathway where there is: c uncontrolled and/or severe symptoms including pain, dyspnoea, haemoptysis, confusion, nausea and vomiting or any other symptom caused by metastatic disease or local invasion c signs of superior venal cava obstruction c stridor.
Criteria for discharge from hospital
Ideally, a team specialising in lung cancer and mesothelioma will care for all inpatients. Where this is not possible, the supervising team should seek appropriate advice from the team: c control all symptoms sufficiently to allow ongoing care in the community c arrange appropriate community support c give patients the opportunity to meet the lung cancer and mesothelioma nurse specialist c give patients and relatives appropriate information about the diagnosis and intended management, including followup c communicate clearly follow-up arrangements to the primary care team.
TUBERCULOSIS
Burden of disease 27 28 Tuberculosis (TB) is a significant public health problem which necessitates that it is viewed in a wider context. Several key areas relating to the control and prevention of TB have been identified in the BTS and NICE guidelines 27 28 including: c notification to allow surveillance and initiate contact tracing of primary cases c local organisational requirements for TB services c measures for the control of TB in hospitals and in prisons c protection of groups with potential exposure to TB including healthcare workers c recognition of high rates of TB in the homeless c management of TB in schools c outbreak contingency planning c new immigrant screening c BCG vaccination and management of positive reactors. Thus TB is managed by an identifiable local team experienced in TB and not in primary care. The local specialist team includes specialist physicians and nurses, microbiologists and public health professionals.
ICD10 codes
Tuberculosis: A15-19.
Ambulatory care
All individuals with suspected TB require urgent specialist outpatient assessment. The aims are to establish a diagnosis, institute appropriate therapy, monitor the response to therapy and assess compliance and side effects of therapy.
Assessment of patients
The assessment and diagnostic process often requires complex and invasive investigations necessitating the input of a range of specialities coordinated by a physician with experience in TB.
Although TB most commonly affects the lungs or lymph nodes, it can be disseminated throughout the body and affect several different organs such as kidney, bowel, bone and joint, central nervous system, skin, pericardium, liver. As well as simple examination of sputum or pus, specialised investigations and biopsies may be required to confirm the diagnosis and assess the extent of spread.
The purpose of the initial specialist assessment is to establish the diagnosis, assess the extent of organ involvement, severity of disease and its complications and predisposing diseases such as HIV infection.
Follow-up by specialist TB team
Subsequent treatment and continuity of care is provided by the specialist physician and specialist nurses.
Treatment is directed according to an individualised management plan. Follow-up will vary from thrice weekly directly observed therapy to a minimum monthly review for the duration of therapy. The TB specialist nurse plays an important role in education and monitoring compliance with therapy.
Criteria for discharge from specialist follow-up
Most individuals who have completed a 6-month standard treatment regimen for TB will not require follow-up. Notable exceptions to this are: c individuals with drug-resistant TB in whom not only is the treatment course longer but follow-up is advocated for 1 year after completion of therapy to exclude recurrence of TB c individuals who have developed complications of TB and those with HIV infection will require prolonged specialist follow-up.
Acute phase of disease Criteria for hospital admission
Most individuals with suspected TB need urgent assessment in a specialist outpatient clinic rather than acute admission. Hospital admission for individuals with suspected or confirmed TB may be required in patients with HIV or suspected highly infectious or multidrug resistant TB. Referral for emergency hospital admission in the acute phase is primarily based on clinical judgement. TB can be disseminated or affect individual organs such as lungs, kidney, bowel, lymph node, central nervous system, skin, bone and joints, pericardium, liver. Thus, individuals can present with a variety of acute illnesses such as pneumonia, bowel obstruction, pericarditis, meningitis or seizures. Drug regimens for TB involve several drugs which have potentially severe side effects such as hepatitis. The initiation of therapy can be associated with side effects that require inpatient assessment and adjustment of therapy.
Criteria for discharge from hospital c After resolution of the acute symptoms, diagnosis and successful initiation of antituberculosis therapy.
c In those who are highly infectious, discharge from hospital is considered safe after 2 weeks of appropriate antituberculosis therapy.
c After resolution of drug-induced side effects and after established on an appropriate antituberculous regime. OBSTRUCTIVE SLEEP APNOEA SYNDROME Burden of disease 31 The prevalence of obstructive sleep apnoea syndrome (OSAS) in middle-aged men is around 2%, a similar prevalence to type 1 diabetes. The prevalence in middle-aged women is estimated at 0.5-1%.
The main clinical consequence of untreated OSAS is the development of undue daytime sleepiness. This is associated with an increased risk for road traffic accidents, impairment of cognitive function and mood swings. A link with adverse cardiac and cerebrovascular events is also suspected.
The condition is now much more widely recognised, in part due to media exposure, and the association with snoring and obesity is appreciated. The great majority of patients will be seen initially in a primary care setting.
Ambulatory care
There is considerable opportunity for development of primary care-based elements of assessment and management of OSAS. Recording of sleep pattern and quality, risk factors for OSAS (persistent snoring, body mass index, hypertension, neck circumference, witnessed apnoeas and nocturnal choking episodes) along with the Epworth Sleepiness Score (ESS) are core data that could readily be acquired in primary care.
There are various models of service delivery in relation to OSAS ranging from entirely inpatient overnight diagnostic sleep study (polysomnography) and continuous positive airway pressure (CPAP) titration favoured in North America to predominantly home sleep study procedures and day visit CPAP strategies widely employed in the UK.
There is a growing acceptance that satisfactory long-term clinical outcomes can be achieved via home/outpatient OSAS services provided access to inpatient polysomnography is maintained.
Criteria for referral to a specialist sleep disordered breathing service
The main purpose for specialist attendance relates to: c evaluation of excess daytime sleepiness in relation to occupational risks (chiefly driving) and consideration of any alternative cause for daytime sleepiness
